NCT03266913 is a Phase 3 clinical trial of Probiotic in Hyperbilirubinemia, Neonatal, sponsored by Hormozgan University of Medical Sciences.

Who is sponsoring NCT03266913?

NCT03266913 is sponsored by Hormozgan University of Medical Sciences.

What drugs are being tested in NCT03266913?

Interventions in NCT03266913: Probiotic.

What condition does NCT03266913 study?

NCT03266913 studies Hyperbilirubinemia, Neonatal.

Is NCT03266913 still recruiting?

NCT03266913 is currently status unknown. Last updated 30 August 2017.

Last reviewed 2017-08-30 · How we verify

NCT03266913

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia

Status unknown Phase 3 Last updated 30 August 2017

What this trial tests

Phase 3 trial testing Probiotic in Hyperbilirubinemia, Neonatal in 126 participants. Status unknown.

Timeline

1 August 2017

Primary endpoint
1 October 2017

1 November 2017

Quick facts

Lead sponsor	Hormozgan University of Medical Sciences
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	126
Start date	1 August 2017
Primary completion	1 October 2017
Estimated completion	1 November 2017
Sites	1 location across Iran

Drugs / interventions tested

Probiotic

Conditions studied

Hyperbilirubinemia, Neonatal — all drugs for Hyperbilirubinemia, Neonatal →

Sponsor

Hormozgan University of Medical Sciences

Who can join

Adults 2 Days to 28 Days, any sex, with Hyperbilirubinemia, Neonatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neonatal Jaundice occurs in 60% of term infants and 80% of premature infants. Although it is transient, it is associated with high rate of readmission of patients in the first week of infancy. Neonatal jaundice can cause neurological complications and kernicterus. Considering the fact that there have been a lot of studies on probiotic role in management of necrotizing enterocolitis (NEC) and few studies on their role in neonatal jaundice, we carried out this study to determine the efficacy and safety of probiotics in neonatal hyperbilirubinemia in infants hospitalized in children hospital in Bandar Abbas.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Probiotic

Trials testing the same drug.

NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
NCT07462481 — Probiotic Improve Constipation · NA · recruiting
NCT07511855 — Stress-buffering and Sleep Disturbance-resilient Effects of a Dual Bifidobacterium Longum Combination Under Short-term T · Phase 2 · not yet recruiting
NCT07474064 — Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC · Phase 2 · not yet recruiting

Other recruiting trials for Hyperbilirubinemia, Neonatal

Currently open trials in the same condition.

NCT03866213 — Validation of a Jaundice Diagnostic and Monitoring Device for Low-Resource Settings · recruiting

Other Hormozgan University of Medical Sciences trials

Trials by the same sponsor.

NCT06670573 — The Relationship Between Allergic Rhinitis, Forward Head Posture, and Anxiety Levels in Iranian Children · completed
NCT06677684 — The Effect of Adjunct Vitamin a on Community-Acquired Pneumonia in Southern Iranian Children: a Randomized Clinical Tria · NA · completed
NCT06665503 — The Impact of Zinc and Probiotics in Preventing Pediatric Antibiotic-Associated Diarrhea in Southern Iran · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03266913 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hormozgan University of Medical Sciences
Last refreshed: 30 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03266913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing